Xilio Therapeutics, Inc.

Contributing Author

Recent Articles by Xilio Therapeutics, Inc.

May-12	Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates XLO GlobeNewswire
May-07	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Apr-17	Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 XLO GlobeNewswire
Apr-16	Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors XLO GlobeNewswire
Apr-03	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Mar-23	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results XLO GlobeNewswire
Mar-17	Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting XLO GlobeNewswire
Mar-12	Xilio Therapeutics Announces 1-for-14 Reverse Stock Split XLO -5.31% GlobeNewswire
Mar-02	Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference XLO GlobeNewswire
Mar-02	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Feb-11	Xilio Therapeutics Announces Pricing of Underwritten Offering XLO +11.44% GlobeNewswire
Jan-08	Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates XLO GlobeNewswire
Nov-13	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results XLO -9.28% GlobeNewswire
Nov-07	Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting XLO GlobeNewswire
Nov-07	Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting XLO GlobeNewswire
Nov-03	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO +6.68% XLO -5.66% GlobeNewswire
Oct-30	Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting XLO GlobeNewswire
Oct-03	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting XLO GlobeNewswire
Oct-02	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Sep-09	Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead XLO +7.81% GlobeNewswire
Aug-14	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results XLO GlobeNewswire
Aug-01	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jul-02	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jun-10	Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors XLO GlobeNewswire
Jun-05	Xilio Therapeutics Announces Closing of $50.0 Million Public Offering XLO GlobeNewswire
Jun-03	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jun-02	Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering XLO -34.57% GlobeNewswire
Jun-02	Xilio Therapeutics Announces Proposed Public Offering XLO -34.57% GlobeNewswire
May-31	Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer XLO GlobeNewswire
May-08	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results XLO +8.03% GlobeNewswire
May-02	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire

Xilio Therapeutics, Inc.

Recent Articles by Xilio Therapeutics, Inc.

Upgrade your Finviz experience